Invo Fertility, Inc. key statistics and ratios
In fiscal 2025, Invo Fertility, Inc. had an operating margin of -105.8%, debt equal to 28.0% of equity and a current ratio of 0.27. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 74.9% | 63.0% | 60.9% | 53.7% | 33.2% | 70.3% | 81.6% | 81.7% | 90.6% | 91.4% | 96.5% | 59.7% | 34.7% | 43.1% | 99.6% | — |
| Operating margin | −983.4% | −979.7% | <−999% | <−999% | <−999% | <−999% | −227.0% | −532.8% | −120.8% | −531.7% | −125.4% | <−999% | −224.0% | −101.5% | −105.8% | −78.7% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −248.9% | −622.2% | −146.4% | −804.7% | −160.0% | <−999% | −266.0% | −141.7% | −340.9% | −92.3% |
| Free-cash-flow margin | — | — | — | — | <−999% | −667.2% | −64.2% | −136.0% | 88.2% | −465.1% | −154.9% | −804.4% | −172.1% | −48.3% | −103.2% | −63.3% |
| Return on equity | — | — | — | — | — | — | — | — | — | — | −102.0% | — | — | −137.4% | — | −58.6% |
| Return on assets | −623.6% | −526.5% | −613.9% | <−999% | <−999% | −490.6% | −254.1% | −589.4% | −168.5% | −131.0% | −63.6% | −159.0% | −72.3% | −28.7% | −70.4% | −30.2% |
| Asset turnover | 0.56 | 0.45 | 0.22 | 0.14 | 0.03 | 0.12 | 1.02 | 0.95 | 1.15 | 0.16 | 0.40 | 0.12 | 0.27 | 0.20 | 0.21 | 0.33 |
| Current ratio | 0.02 | 0.02 | 0.02 | 0.02 | 0.13 | 0.05 | 0.05 | 0.21 | 1.03 | 4.61 | 5.37 | 0.19 | 0.16 | 0.07 | 0.27 | 0.71 |
| Debt to equity | — | — | — | — | — | — | — | — | — | 12.1% | — | — | 140.5% | 59.3% | 28.0% | 9.9% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m | n/m |
| R&D as % of revenue | — | — | — | — | — | — | — | — | 0.0% | 38.4% | 5.2% | 66.2% | 5.5% | 0.1% | — | — |
| SG&A as % of revenue | >999% | >999% | >999% | >999% | >999% | >999% | 308.6% | 614.5% | 211.4% | 584.7% | 216.7% | >999% | 247.8% | 123.5% | 112.4% | 106.5% |
| Capital spending as % of revenue | — | — | — | — | 0.0% | 30.8% | 0.0% | 3.9% | 4.4% | 4.7% | 10.0% | 1.3% | 14.7% | 2.8% | 0.6% | 0.0% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 31.0% | 39.7% | 35.0% | 99.8% | — | — | 99.7% | 97.2% |
| Operating margin | −90.7% | −116.6% | −73.3% | −160.4% | −93.1% | −89.2% | −78.9% | −59.3% |
| Net margin | −113.8% | −224.6% | <−999% | −194.2% | −193.3% | 69.2% | −274.9% | 40.9% |
| Free-cash-flow margin | −44.7% | −41.3% | −217.5% | −92.6% | −101.6% | 0.8% | — | −50.6% |
| Current ratio | 0.23 | 0.07 | 0.08 | 0.12 | 0.12 | 0.27 | 0.90 | 0.71 |
| Debt to equity | — | 59.3% | — | — | 34.1% | 28.0% | 12.7% | 9.9% |
| R&D as % of revenue | 0.0% | 0.0% | 16.2% | — | — | — | — | — |
| SG&A as % of revenue | 105.7% | 146.1% | 95.1% | 117.7% | 121.1% | 114.5% | 108.0% | 87.6% |
Financial health
- Short-term assets cover short-term liabilities $5m of assets due within a year against $7m of liabilities due within a year.
- Short-term assets cover long-term liabilities $5m short-term assets against $3m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Debt is 10% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$5m of operating cash flow against $2m of debt.
- Operating profit covers interest at least five times over Operating income of −$6m against $1m of interest.
Moat
Weak moat
How hard Invo Fertility's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median -179.6% of total assets over 10 years.
- Pricing power 12 / 20
Gross margin has been a median 80.7%, moving by 19.5 percentage points (standard deviation) across 10 years.
- Durability 10 / 20
Operating margin has been a median -268.6%; its worst year was -816.7%.
- Cash conversion 2 / 20
Free cash flow was positive in 1 of 6 years, at a median -80.3% of revenue.
- Discipline 10 / 20
The diluted share count fell 88.5% over five years; stock-based pay has been a median 64.3% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Beyond Air, Inc. statistics
- Anbio Biotechnology statistics
- Nuwellis, Inc. statistics
- Milestone Scientific Inc. statistics
- Neuroone Medical Technologies Corp statistics
Head to head: IVF vs XAIRIVF vs NNNNIVF vs NUWE
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies